Idorsia Ltd - ESG Rating & Company Profile powered by AI
This assessment of Idorsia Ltd employs data points from across the web and also from public documents by Idorsia Ltd. This article contains a Q&A table on Idorsia Ltd. This ESG score includes seventeen UN SDGs including: 'No Poverty', 'Sustainable Cities & Communities' and 'Peace, Justice & Strong Institutions'.
Idorsia Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 6.9, social score of 6.0 and governance score of 7.0.
6.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 432 | Twist Bioscience Corp | 6.8 | High |
| 432 | Rhythm Pharmaceuticals Inc | 6.8 | High |
| 446 | Idorsia Ltd | 6.7 | High |
| 446 | Actinium Pharmaceuticals Inc | 6.7 | High |
| 446 | AnGes Inc | 6.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Idorsia Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Idorsia Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Idorsia Ltd report the average age of the workforce?
Sign up for free to unlockDoes Idorsia Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Idorsia Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Idorsia Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Idorsia Ltd offer flexible work?
Sign up for free to unlockDoes Idorsia Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Idorsia Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Idorsia Ltd conduct supply chain audits?
Sign up for free to unlockDoes Idorsia Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Idorsia Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Idorsia Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Idorsia Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Idorsia Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Idorsia Ltd disclose water use targets?
Sign up for free to unlockDoes Idorsia Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Idorsia Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Idorsia Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Idorsia Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Idorsia Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Idorsia Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Idorsia Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Idorsia Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Idorsia Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Idorsia Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Idorsia Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Idorsia Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Idorsia Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Idorsia Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Idorsia Ltd disclose its waste policy?
Sign up for free to unlockDoes Idorsia Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Idorsia Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Idorsia Ltd disclose energy use targets?
Sign up for free to unlockDoes Idorsia Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Idorsia Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Idorsia Ltd
These potential risks are based on the size, segment and geographies of the company.
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.